Literature DB >> 7575604

Inactivation of NF-kappa B inhibitor I kappa B alpha: ubiquitin-dependent proteolysis and its degradation product.

C C Li1, R M Dai, D L Longo.   

Abstract

In most cells, the inactive dimeric NF-kappa B complexes are retained in the cytoplasm by binding to a group of inhibitory proteins. I kappa B. In response to extracellular stimuli, I kappa B is rapidly phosphorylated and degraded, thus, liberating the active NF-kappa B. To investigate the mechanisms involved, we have developed a cell-free system to study the degradation of the prototype I kappa B protein, I kappa B alpha. In this in vitro assay, ubiquitin, proteasome-containing S100 fraction and ATP are required for the proteolysis of I kappa B alpha. Both bound and free forms of I kappa B alpha isolated from intact cells can be degraded through this pathway. We also identified polyubiquitinated I kappa B alpha molecules and N-terminal truncated I kappa B alpha degradation product(s) both in vivo and in vitro. We conclude that the inactivation of I kappa B alpha occurs through a series of processes including phosphorylation, ATP-dependent ubiquitin conjugation and proteasome-mediated proteolysis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7575604     DOI: 10.1006/bbrc.1995.2465

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

Review 1.  Control of NF-kappa B transcriptional activation by signal induced proteolysis of I kappa B alpha.

Authors:  R T Hay; L Vuillard; J M Desterro; M S Rodriguez
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-09-29       Impact factor: 6.237

2.  Linkage of the ubiquitin-conjugating system and the endocytic pathway in ligand-induced internalization of the growth hormone receptor.

Authors:  R Govers; P van Kerkhof; A L Schwartz; G J Strous
Journal:  EMBO J       Date:  1997-08-15       Impact factor: 11.598

3.  Cranberry A-type proanthocyanidins selectively target acute myeloid leukemia cells.

Authors:  Laura M Bystrom; Daniel P Bezerra; Hsiao-Ting Hsu; Hongliang Zong; Luis A Lara-Martínez; Jeanne P De Leon; Megan Emmanuel; David Méry; Sara Gardenghi; Duane Hassane; Catherine C Neto; Susanna Cunningham-Rundles; Michael W Becker; Stefano Rivella; Monica L Guzman
Journal:  Blood Adv       Date:  2019-11-12

Review 4.  Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development.

Authors:  Alisa B Lee-Sherick; Rachel M A Linger; Lia Gore; Amy K Keating; Douglas K Graham
Journal:  Br J Haematol       Date:  2010-08-31       Impact factor: 6.998

5.  Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFĸB pathway.

Authors:  Ilana Chefetz; Jennie C Holmberg; Ayesha B Alvero; Irene Visintin; Gil Mor
Journal:  Cell Cycle       Date:  2011-07-01       Impact factor: 4.534

6.  Signal-dependent degradation of IkappaBalpha is mediated by an inducible destruction box that can be transferred to NF-kappaB, bcl-3 or p53.

Authors:  F G Wulczyn; D Krappmann; C Scheidereit
Journal:  Nucleic Acids Res       Date:  1998-04-01       Impact factor: 16.971

Review 7.  Regulation of IkappaBalpha function and NF-kappaB signaling: AEBP1 is a novel proinflammatory mediator in macrophages.

Authors:  Amin Majdalawieh; Hyo-Sung Ro
Journal:  Mediators Inflamm       Date:  2010-04-12       Impact factor: 4.711

8.  Dynamic change of TNIK in response to tumor necrosis factor alpha in a TRAF2-dependent manner.

Authors:  Jinghua Gui; Zhenhai Li; Xiumei Zhou
Journal:  Hum Cell       Date:  2013-01-26       Impact factor: 4.174

9.  Mediation by NF-kappa B of cytokine induced expression of intercellular adhesion molecule 1 (ICAM-1) in an intestinal epithelial cell line, a process blocked by proteasome inhibitors.

Authors:  C Jobin; C Hellerbrand; L L Licato; D A Brenner; R B Sartor
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

10.  A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.

Authors:  Christopher Lieu; Laura Chow; A Scott Pierson; S Gail Eckhardt; Cindy L O'Bryant; Mark Morrow; Zung Vu Tran; John J Wright; Lia Gore
Journal:  Invest New Drugs       Date:  2008-07-11       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.